Sustainable healthcare is too often framed as a cost, a compliance obligation, or a long-term ambition. Health Innovation Hub Ireland’s new report, The Green Dividend: Why Sustainability is Ireland’s Health and Enterprise Opportunity, presents the opposite – evidence of an immediate and growing return for both enterprise and health. It reframes how our health system, our enterprise agencies and our clinical leaders should think about sustainability: not as a cost to be managed, but as a return already being earned.
The report debunks the ‘sustainability costs more’ assumption. Take remanufactured medical devices: Life cycle analysis of electrophysiology catheters shows CO₂ emission reductions of 50-60 per cent per device turn, with cost savings of 30-50 per cent compared to virgin devices.
At Bon Secours Hospital Cork, a remanufacturing partnership with Vanguard Medical Devices generated over €48,000 in savings and diverted more than 41kg of medical device waste from incineration across three years. MedFirst Supplies’ Safe Clean Box, a closed cabin decontamination system in use at the Mater, cut non-conformances in half, saved 160 staff hours a year, delivered roughly €32,000 in annual savings, with an 82 per cent reduction in energy use compared to ultrasonic cleaners. Ecco Spray’s refillable ultrasound gel system, piloted by HIHI at University Hospital Galway, eliminated plastic gel sachets entirely from participating scans and cut gel volume per scan by 95 per cent, with no reduction in patient comfort and no change to clinical workflow. The common thread in this evidence? Environmental performance and clinical usability are not in tension. When real evidence in real clinical settings is generated, sustainable alternatives hold up.
From April 2027, all NHS suppliers – regardless of size – will be required to publish comprehensive Carbon Reduction Plans covering full Scope 1, 2 and 3 emissions. For Irish SMEs and start-ups for whom the UK is a primary export market, that’s a direct and growing pressure. Companies that can demonstrate clinical validation, lifecycle evidence and sustainability credentials will gain access. Those that cannot will find doors closing.
The EU picture reinforces this. The Ecodesign for Sustainable Products Regulation, the Packaging and Packaging Waste Regulation, and the Corporate Sustainability Reporting Directive are moving circularity and carbon accountability from voluntary commitment to compliance requirement across manufacturing and procurement. The market is not waiting for Ireland to catch up.
Ireland’s life sciences sector is a natural base for developing the low-carbon, circular product alternatives the global market is increasingly demanding. Early clinical validation through HIHI confers credibility in international markets. It converts sustainability from a regulatory compliance challenge into a competitive export advantage. The economic opportunity spans circular medical plastics, reusable devices, sustainable packaging, low carbon manufacturing and digital health, each representing growing procurement requirements in markets that are formalising sustainability criteria year on year.
The global healthcare sector represents almost 10 per cent of world GDP, with 70 per cent of its emissions arising from supply chain production, packaging and disposal, hence, the consequential area for cutting the sector’s footprint sits in procurement decisions, not clinical practice.
Ireland’s own procurement infrastructure has not kept pace. The OECD (2025) confirms healthcare procurement is the largest single category of government procurement and green procurement policy. Our health system does not systematically measure emissions across all three Scope areas, leaving Scope 3 supply chain emissions – the single largest contributor to health sector carbon footprints internationally – largely unquantified. Healthcare is notably absent as a named priority sector in Ireland’s first Whole-of-Government Circular Economy Strategy 2026-2028, despite our health system being among the country’s largest purchasers of single-use products. Countries that adapt early will benefit from reduced costs, improved compliance and leadership opportunities in sustainable healthcare innovation.
Programmes and mechanisms alone are insufficient without visible leadership, prioritisation at the highest level, and commitment to act swiftly at the scale the opportunity demands. The green dividend cannot be claimed through aspiration. It is returned through procurement frameworks that reward lifecycle evidence, through Regional Health Areas that embed validated innovations into their operating models, through ring-fenced funding that closes the gap between regulatory compliance and market readiness, and through policy coherence that puts health care at the centre of Ireland’s circular economy ambition. This requires commitment from four system partners:
• The Department of Health should fund green procurement pilots that generate lifecycle and circularity evidence.
• The HSE should support full Scope 1, 2 and 3 emissions reporting with facility-level visibility, and embed life cycle costing into tender frameworks.
• Enterprise Ireland should help Irish life sciences companies design ahead of the EU regulatory curve rather than scrambling to catch it.
• The Department of Climate, Energy and the Environment should name health care as a priority sector in the next iteration of the Circular Economy Strategy.
Ireland is home to over 450 medtech companies and is one of Europe’s leading life sciences hubs, with the clinical network, the research base, and, through programmes like HIHI’s GreenTech in Health, the testbed infrastructure to generate the evidence international markets are demanding. The question now is whether Irish health care will build the systems to claim that advantage at scale or allow companies with stronger sustainability credentials to take the market instead.
Eimear Galvin is Regional Manager and National GreenTech in Health Lead at Health Innovation Hub Ireland. The full report, ‘The Green Dividend: Why Sustainability is Ireland’s Health and Enterprise Opportunity’, is available from HIHI.
Add Comment